Advancing cell and gene therapies from preclinical to clinical stages requires tackling critical manufacturing hurdles. Donor variability, cryopreservation, scalability, and equipment choices, including the use of bioreactors, all impact product quality, reproducibility, and regulatory readiness. This workshop explores practical strategies to strengthen manufacturing systems, mitigate risk, and ensure a smooth transition into the clinic.

Join this workshop to:

• Understand how donor variability and cryopreservation affect product quality, and ways to reduce these risks
• Explore scalability, bioreactor implementation, and equipment decisions that drive consistency and compliance
• Review case-based approaches for moving from preclinical data to robust clinical programs